ACCESS GROWTH CAPITAL THROUGH THE PUBLIC MARKETS

TSX and TSX Venture Exchange list leading public Life Sciences companies from Canada and around the world.

Omar Khafagy

Omar Khafagy

Head, Life Sciences
Toronto Stock Exchange and TSX Venture Exchange

LIFE SCIENCES Updates

A collection of videos focused on insights for accessing growth capital through the public markets with industry experts.

KEY BENEFITS FOR LIFE SCIENCES COMPANIES

$27B
in market capitalization
49%
of Life Sciences companies currently listed on TSX are graduates
  • 1
    Access To Capital And Future Financing Opportunities
    Going public can provide your company with financing opportunities to grow your business while expanding and diversifying your investor base by giving you access to pools of capital in Canada, the U.S. and globally.
  • 2
    Facilitate Growth
    As a public company, your shares can be used as a currency substitute to acquire target companies, instead of a direct cash offering.
  • 3
    Increase Visibility And Prestige
    Going public enhances your company’s visibility which can provide your company with a higher profile and greater credibility.
  • 4
    Provide Liquidity For Shareholders
    Becoming a public company establishes a market for your company’s shares, providing your investors with an efficient and regulated vehicle in which to trade their shares.
  • 5
    Create Employee Incentive Mechanisms
    Your employees can participate in the ownership of your company and benefit from being shareholders. This can serve to ensure stronger employee commitment to your company’s performance and success.

GO PUBLIC - WAYS TO GET LISTED

There are multiple pathways to listing on TSX and TSXV.

TSX and TSXV Listed company initiatives

TSX VENTURE 50®

TSX Venture 50 is a ranking of the 50 top-performing companies on TSX Venture Exchange over the last year. Companies are ranked based on three equally-weighted criteria of one-year share price appreciation, market capitalization increase, and Canadian consolidated trading value.

Meet the top performers at https://www.tsx.com/venture50

TSX30

TSX30 recognizes the 30 top-performing companies on Toronto Stock Exchange, ranked based on dividend-adjusted share price performance over a three-year period. As our flagship program, it offers unique insight into important market trends and shines a light on compelling companies that have exemplified excellence in growth.

Explore the list at https://www.tsx.com/tsx30

Life Sciences Statistics

7

new Life Sciences listings
in 2024

$9B

Life Sciences equity capital raised
in the last 5 years

536

Life Sciences financings
in the last 5 years

All data as of December 31, 2024.

Market Intelligence Report (MiG)

Provides year-to-date data on listings, financings and trading activity across Toronto Stock Exchange and TSX Venture Exchange, broken down by sector and region.

GET OUR MIG REPORT

WHAT INDUSTRY EXPERTS ARE SAYING

TMX POV - What TSX Venture 50™ Tells Us About Liquidity (And why we are fighting for consolidated data on TSXV)
There are two numbers that put the achievements of the 2025 TSX Venture 50™ into perspective. First, the 50 companies on the list had an average share price increase of 207% during 2024. Then secondly during 2024 these companies created $16.1B of new market capitalization.
Read more
TMX POV - ‘Made-in-Canada’ investment taxonomy an important step forward
The federal government recently announced a plan to deliver “Made-in-Canada” sustainable investment guidelines, as well as mandatory climate-related financial disclosures for large, federally incorporated private companies.
Read more
TMX POV - The Venture Index Tells A Story (It Just Might Not Be What You Think)
The S&P/TSX Venture Composite Index* (“Venture Index”), like many small and microcap indices, can be quite misunderstood. So let’s take a step back and see how it is constructed and what happens to the best companies in it.
Read more
TMX POV - Capital Pool CompanyⓇ Program: A Strategic Approach to Roll-up Acquisitions
In today's rapidly evolving business landscape, growth and expansion are paramount to many firms. Acquisitions have emerged as common strategies to achieve this, but traditional methods may frequently require significant capital and can result in increased debt.
Read more
TMX POV - Expanding SR&ED to public companies benefits Canada
In the wake of the federal government’s 2024 budget, the overwhelming focus for the tech and innovation sector has been on the increase to the capital gains inclusion rate. But the budget also included a very positive announcement for innovation – the commitment to explore extending enhanced SR&ED tax credits to public companies, which was followed by the release of a consultation on that very question.
Read more

More Info

Dual-Listing Guide

Dual-Listing Guide

A detailed guide for public companies looking to dual list.

Guide to Listing

Guide to Listing

Market overview, listing requirements & vehicles, and sector profiles.

Technical Guide

Technical Guide

A more detailed guide to listing on TSX and TSXV.

HAVE A QUESTION?

Contact us at lifesciences@tmx.com and we will be happy to assist you.